Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

• ClinicalTrials.gov Identifier: NCT03245151
• Recruitment Status: Completed
• First Posted: August 10, 2017
• Last Update Posted: January 30, 2023
• Sponsor: Eisai Inc.
• Collaborator: Merck Sharp & Dohme LLC
• Information provided by (Responsible Party): Eisai Inc.

Study Description

Brief Summary:

Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with everolimus once daily to pediatric participants with recurrent/refractory solid tumors. Phase 2, utilizing Simon's optimal 2-stage design, will be conducted to estimate the antitumor activity of lenvatinib in combination with everolimus in pediatric participants with selected recurrent/refractory solid tumors including Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET), rhabdomyosarcoma, and high grade glioma (HGG) using objective response rate (ORR) at Week 16 as the outcome measure.

Condition or disease	Intervention/treatment	Phase
Recurrent and Refractory Solid Tumors	Drug: Lenvatinib; Drug: Everolimus	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 64 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
• Actual Study Start Date: November 16, 2017
• Actual Primary Completion Date: September 30, 2022
• Actual Study Completion Date: September 30, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Phase 1: Phase 1; Recurrent or refractory solid tumors; During Phase 1 (Treatment Phase: 1 cycle; 28 days of treatment), utilizing a rolling 6 design, participants with recurrent or refractory solid tumors will receive escalating doses of lenvatinib in combination with everolimus for determination of the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Participants who complete 1 cycle of treatment will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.	Drug: Lenvatinib; oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension; Drug: Everolimus; 2 mg, 3 mg, or 5 mg tablets for oral suspension
Experimental: Phase 2: Cohort 1, Ewing sarcoma/pPNET; During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET) (Cohort 1) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1. Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.	Drug: Lenvatinib; oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension; Drug: Everolimus; 2 mg, 3 mg, or 5 mg tablets for oral suspension
Experimental: Phase 2: Cohort 2, Rhabdomyosarcoma; During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory rhabdomyosarcoma (Cohort 2) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks of treatment). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.	Drug: Lenvatinib; oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension; Drug: Everolimus; 2 mg, 3 mg, or 5 mg tablets for oral suspension
Experimental: Phase 2: Cohort 3, High Grade Glioma (HGG); During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory HGG (Cohort 3) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.	Drug: Lenvatinib; oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension; Drug: Everolimus; 2 mg, 3 mg, or 5 mg tablets for oral suspension

Outcome Measures

Primary Outcome Measures :

1. Maximum tolerated dose (MTD) of lenvatinib in combination with everolimus: Phase 1 [ Time Frame: Cycle 1 (Day 1 to Day 28) of the Treatment Phase ]
   The sponsor and Protocol Steering Committee will review all participants' safety and clinical data to determine the MTD of the combination of lenvatinib with everolimus. If 2 or more of a cohort of up to 6 participants experience dose-limiting toxicities (DLTs: side effects that prevent a dose increase) at a given dose level, then the MTD has been exceeded and dose escalation will be stopped.
2. Recommended Phase 2 dose (RP2D) of lenvatinib in combination with everolimus: Phase 1 [ Time Frame: Cycle 1 (Day 1 to Day 28) of the Treatment Phase ]
   The sponsor and Protocol Steering Committee will review all participants' safety and clinical data to determine the MTD of the combination of lenvatinib with everolimus. If 2 or more of a cohort of up to 6 participants experience DLTs (side effects that prevent a dose increase) at a given dose level, then the MTD has been exceeded and dose escalation will be stopped. The RP2D is determined based on the MTD and DLTs.
3. Number of participants with any treatment-emergent (TE) serious adverse event (SAE) in Phase 1, as a measure of the safety and toxicity of lenvatinib in combination with everolimus [ Time Frame: From date of first dose up to 28 days after the last dose of study treatment, up to approximately 2 years ]
   An SAE is any untoward medical occurrence that at any dose: results in death; is life threatening (ie, the participant was at immediate risk of death from the adverse event [AE] as it occurred; this does not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). A TEAE is defined as an AE that emerges during treatment, having been absent at pretreatment (baseline) or (1) reemerges during treatment, having been present at pretreatment (baseline) but stopped before treatment, or (2) worsens in severity during treatment relative to the pretreatment state, when the AE is continuous.
4. Number of participants with any TE adverse event (TEAE) in Phase 1, as a measure of the safety and toxicity of lenvatinib in combination with everolimus [ Time Frame: From date of first dose up to 28 days after the last dose of study treatment, up to approximately 2 years ]
   An AE is any untoward medical occurrence in a patient or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with the medicinal product. A TEAE is defined as an AE that emerges during treatment, having been absent at pretreatment (baseline) or (1) reemerges during treatment, having been present at pretreatment (baseline) but stopped before treatment, or (2) worsens in severity during treatment relative to the pretreatment state, when the AE is continuous.
5. Overall Response Rate (ORR) at Week 16 for Phase 2 [ Time Frame: Week 16 ]
   ORR is defined as the proportion of participants who have the best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (for Ewing sarcoma/peripheral primitive neuroectodermal tumor [pPNET] and rhabdomyosarcoma) or Response Assessment in Neuro-Oncology (RANO) Criteria (for high grade glioma [HGG]).

Secondary Outcome Measures :

1. ORR at the time of data cutoff: Phase 1 [ Time Frame: up to Week 4 of the Treatment Phase; up to 2 years in the Extension Phase ]
   ORR is defined as the proportion of participants with a BOR of CR or PR per RECIST 1.1 (for Ewing sarcoma/pPNET and rhabdomyosarcoma) or RANO Criteria (for HGG).
2. ORR at the time of data cutoff: Phase 2 [ Time Frame: up to Week 16 of the Treatment Phase; up to 2 years in the Extension Phase ]
   ORR is defined as the proportion of participants with a BOR of CR or PR per RECIST 1.1 (for Ewing sarcoma/pPNET and rhabdomyosarcoma) or RANO Criteria (for HGG only).
3. Disease Control Rate (DCR): Phase 1 [ Time Frame: up to Week 4 of the Treatment Phase; up to 2 years in the Extension Phase ]
   DCR is defined as the proportion of participants with a BOR of CR, PR, or stable disease (SD) (SD duration ≥7 weeks since the first dose of the study treatment) per RECIST 1.1 (for Ewing sarcoma/pPNET and rhabdomyosarcoma) or RANO Criteria (for HGG only).
4. DCR: Phase 2 [ Time Frame: up to Week 16 of the Treatment Phase; up to 2 years in the Extension Phase ]
   DCR is defined as the proportion of participants with a BOR of CR, PR, or SD (SD duration ≥7 weeks since the first dose of the study treatment) per RECIST 1.1 (for Ewing sarcoma/pPNET and rhabdomyosarcoma) or RANO Criteria (for HGG only).
5. Clinical Benefit Rate (CBR): Phase 1 [ Time Frame: up to Week 4 of the Treatment Phase; up to 2 years in the Extension Phase ]
   CBR is defined as the proportion of participants with a BOR of CR, PR, or durable SD (SD duration ≥23 weeks since the first dose of the study treatment) per RECIST 1.1 (for Ewing sarcoma/pPNET and rhabdomyosarcoma) or RANO Criteria (for HGG only).
6. CBR: Phase 2 [ Time Frame: up to Week 16 of the Treatment Phase; up to 2 years in the Extension Phase ]
   CBR is defined as the proportion of participants with a BOR of CR, PR, or durable SD (SD duration ≥23 weeks since the first dose of the study treatment) per RECIST 1.1 (for Ewing sarcoma/pPNET and rhabdomyosarcoma) or RANO Criteria (for HGG only).
7. Duration of Response (DOR): Phase 1 [ Time Frame: up to Week 4 of the Treatment Phase; up to 2 years in the Extension Phase ]
   DOR is defined as the time from the date of the first documented CR or PR to the date of the disease progression objectively documented or death (whichever occurs first). CR, PR, and disease progression will be defined per RECIST 1.1 (for Ewing sarcoma/pPNET and rhabdomyosarcoma) or RANO Criteria (for HGG only).
8. DOR: Phase 2 [ Time Frame: up to Week 16 of the Treatment Phase; up to 2 years in the Extension Phase ]
   DOR is defined as the time from the date of the first documented CR or PR to the date of the disease progression objectively documented or death (whichever occurs first). CR, PR, and disease progression will be defined per RECIST 1.1 (for Ewing sarcoma/pPNET and rhabdomyosarcoma) or RANO Criteria (for HGG only).
9. Area under the plasma concentration time course profile (AUC): Phase 1 [ Time Frame: Lenvatinib: Cycle 1 Day 1 (C1D1), C1D2, C1D15, C1D22, C2D1, C3D1; Everolimus: C1D1, C1D2, C1D15, C1D22 ]
   AUC represents the overall amount of drug in the bloodstream after dosing. AUC will be estimated by non-compartmental methods. Blood samples for plasma concentrations of lenvatinib and whole blood concentrations of everolimus will be collected from all participants.
10. AUC: Phase 2 [ Time Frame: Lenvatinib and everolimus: C1D1, C1D15, Cycles 2 and 3 ]
    AUC represents the overall amount of drug in the bloodstream after dosing. AUC will be estimated by non-compartmental methods. Blood samples for plasma concentrations of lenvatinib and whole blood concentrations of everolimus will be collected from all participants.
11. Maximum observed concentration (Cmax): Phase 1 [ Time Frame: Lenvatinib: Cycle 1 Day 1 (C1D1), C1D2, C1D15, C1D22, C2D1, C3D1; Everolimus: C1D1, C1D2, C1D15, C1D22 ]
    Cmax is the highest concentration of drug in the blood that is measured after a dose. Cmax will be estimated by non-compartmental methods.
12. Cmax: Phase 2 [ Time Frame: Lenvatinib and everolimus: C1D1, C1D15, Cycles 2 and 3 ]
    Cmax is the highest concentration of drug in the blood that is measured after a dose. Cmax will be estimated by non-compartmental methods.
13. Time from dosing to the maximum observed concentration (Tmax): Phase 1 [ Time Frame: Lenvatinib: Cycle 1 Day 1 (C1D1), C1D2, C1D15, C1D22, C2D1, C3D1; Everolimus: C1D1, C1D2, C1D15, C1D22 ]
    Tmax is the time to the highest concentration of drug in the blood that is measured after a dose. Tmax will be estimated by non-compartmental methods.
14. Tmax: Phase 2 [ Time Frame: Lenvatinib and everolimus: C1D1, C1D15, Cycles 2 and 3 ]
    Tmax is the time to the highest concentration of drug in the blood that is measured after a dose. Tmax will be estimated by non-compartmental methods.
15. Number of participants with any TE SAE in Phase 2, as a measure of the safety and toxicity of lenvatinib in combination with everolimus [ Time Frame: From date of first dose up to 28 days after the last dose of study treatment, up to approximately 2.5 years ]
    An SAE is any untoward medical occurrence that at any dose: results in death; is life threatening (ie, the participant was at immediate risk of death from the AE as it occurred; this does not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). A TEAE is defined as an AE that emerges during treatment, having been absent at pretreatment (baseline) or (1) reemerges during treatment, having been present at pretreatment (baseline) but stopped before treatment, or (2) worsens in severity during treatment relative to the pretreatment state, when the AE is continuous.
16. Number of participants with any TEAE in Phase 2, as a measure of the safety and toxicity of lenvatinib in combination with everolimus [ Time Frame: From date of first dose up to 28 days after the last dose of study treatment, up to approximately 2.5 years ]
    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with the medicinal product. A TEAE is defined as an AE that emerges during treatment, having been absent at pretreatment (baseline) or (1) reemerges during treatment, having been present at pretreatment (baseline) but stopped before treatment, or (2) worsens in severity during treatment relative to the pretreatment state, when the AE is continuous.

Eligibility Criteria

• Ages Eligible for Study: 2 Years to 21 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

• ≥2 years and <18 years of age for enrolment in Phase 1 or ≥2 years and ≤21 years of age for enrolment in Phase 2.

• Recurrent or refractory solid tumors

  • Phase 1: All solid tumors (measurable or evaluable disease), including primary central nervous system (CNS) tumors; exclusion of hepatoblastoma and lymphomas. Participants with diffuse intrinsic pontine glioma, optic pathway glioma, or pineal tumors with elevated tumor markers (alpha-fetoprotein [AFP] and beta-human chorionic gonadotropin [ß-hCG][or human chorionic gonadotropin [hCG])do not require histological or cytological confirmation of diagnosis
  • Phase 2: Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET), Rhabdomyosarcoma, High Grade Glioma (HGG) (all must have measurable disease); exclusion of Diffuse Intrinsic Pontine Glioma
• Histologically or cytologically confirmed diagnosis

• Measurable disease that meets the following criteria (Phase 2):

  1. RECIST 1.1 (for all tumor types except HGG): At least 1 lesion of ≥1.0 cm in the longest diameter for a non lymph node or ≥1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using computed tomography /magnetic resonance imaging (CT/MRI)
  2. Response Assessment in Neuro-Oncology (RANO) for high grade glioma (HGG): At least one lesion must be measurable as defined as a bi dimensionally contrast enhancing lesion with clearly defined margins by CT or MRI scan, with a minimal diameter of 1 cm, and visible on 2 axial slices which are preferably at most 5 mm apart with 0 mm skip

Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion

• Karnofsky performance score ≥50 for participants>16 year of age and Lansky play score ≥50 for participants ≤16 years of age. Neurologic deficits in participants with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score

• Prior Therapy

  • Participants must have fully recovered from the acute toxic effects of all prior anti-cancer therapy
  • Cytotoxic chemotherapy or other chemotherapy known to be myelosuppressive: ≥21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
  • Anti-cancer agents not known to be myelosuppressive (eg, not associated with reduced platelet or absolute neutrophil counts): ≥7 days after the last dose of agent
  • Monoclonal antibodies: ≥21 days or 3 half-lives (whichever is shorter) of the antibody must have elapsed after the last dose of a monoclonal antibody (including checkpoint inhibitors). Toxicity related to prior antibody therapy must be recovered to Grade ≤1
  • Corticosteroids: If used to modify immune adverse events related to prior therapy, ≥14 days must have elapsed since last dose of corticosteroid. Participants receiving corticosteroids, who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment, are not eligible
  • Hematopoietic growth factors: ≥14 days after the last dose of a long-acting growth factor or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur
  • Interleukins, interferons, and cytokines (other than hematopoietic growth factors): ≥21 days after the completion of interleukins, interferons or cytokines (other than hematopoietic growth factors)
  • Stem cell infusions (with or without total body irradiation): Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocytes infusion or boost infusion: ≥84 days after infusion and no evidence of graft versus host disease; Autologous stem cell infusion including boost infusion: ≥42 days
  • Cellular Therapy: ≥42 days after the completion of any type of cellular therapy (eg, modified T cells, natural killer cells, dendritic cells, etc)
  • Radiotherapy (XRT)/External Beam Irradiation including Protons: ≥14 days after local XRT; ≥150 days after total body irradiation, craniospinal XRT or if radiation to ≥50% of the pelvis; ≥42 days if other substantial bone marrow radiation.
  • Radiopharmaceutical therapy: ≥42 days after systemically administered therapy.
  • Vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-targeted or mammalian target of rapamycin (mTOR)-targeted therapies: Must not have received prior exposure to lenvatinib; May have previously progressed on an mTOR inhibitor; No more than 2 prior VEGF/VEGFR-targeted therapies (For Phase 2 only); Must not have received prior VEGF/VEGFR-targeted therapy in combination with an mTOR inhibitor (For Phase 2 only)
• Adequate bone marrow function for participants with solid tumors without known bone marrow involvement
• Adequate bone marrow function for participants with known bone marrow metastatic disease
• Adequate renal function
• Adequate liver function
• Adequate cardiac function
• Adequate neurologic function
• Adequate blood pressure (BP) control with or without antihypertensive medications
• Adequate coagulation
• Adequate pancreatic function
• Adequate metabolic function
• Adequate glycemic control
• Participants must have a minimum body surface area (BSA) of 0.6 m^2 at study entry.

Exclusion Criteria

• Participants who have had or are planning to have the following invasive procedures

  • Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrolment
  • Central line placement or subcutaneous port placement is not considered major surgery. External central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment
  • Fine needle aspirate within 7 days prior to enrolment
  • Surgical or other wounds must be adequately healed prior to enrolment
  • For purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy
• Participants who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrolment
• Participants having an active infection requiring systemic therapy.
• Participants with a known history of active hepatitis B (defined as hepatitis B surface antigen reactive or hepatitis B virus- deoxyribonucleic [DNA] detected) or known active hepatitis C virus (HCV, defined as HCV- Ribonucleic acid [RNA] detected). Note: No testing for hepatitis B and hepatitis C is required unless mandated by the local health authority.
• Known to be human immunodeficiency virus (HIV) positive. Note: HIV testing is required at screening only when mandated by the local health authority
• Clinical evidence of nephrotic syndrome prior to enrolment
• Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half teaspoon) within 21 days prior to enrolment
• Thrombotic/ thromboembolic event requiring systemic anticoagulation within 90 days prior to enrollment
• Evidence of new intracranial hemorrhage of more than punctate size on MRI assessment obtained within 28 days prior to study enrollment for Participants with HGG
• Diagnosis of lymphoma
• Radiographic evidence of major blood vessel invasion/infiltration.
• Evidence of untreated CNS metastases (exception: participants with primary CNS tumors and leptomeningeal disease)
• Participants who are currently receiving enzyme-inducing anticonvulsants
• Participants chronically receiving strong cytochrome P450 3A4 (CYP3A4)/P-glycoprotein (P-gp) inhibitors or inducers within 7 days prior to study enrollment
• Females who are breastfeeding or pregnant. For females of childbearing potential, a negative screening pregnancy test must be obtained within 72 hours before the first dose of study drug
• Males who have not had a successful vasectomy (confirmed azoospermia) or if they and their female partners do not meet the criteria above (that is, not of childbearing potential or practicing highly effective contraception throughout the study period and for 7 days after lenvatinib discontinuation or 4 weeks after discontinuation of everolimus). No sperm donation is allowed during the study period and for 7 days after lenvatinib discontinuation or 4 weeks after discontinuation of everolimus.

Contacts and Locations

Locations

United States, Alabama

Children's Hospital of Alabama

Birmingham, Alabama, United States, 35233

United States, Arizona

Phoenix Children's Hospital

Phoenix, Arizona, United States, 85016

United States, California

Loma Linda University Medical Center

Loma Linda, California, United States, 92350

Miller Children's and Women's Hospital

Long Beach, California, United States, 90806

Children's Hospital of Los Angeles

Los Angeles, California, United States, 90027

Southern California Permanente Medical Group

Los Angeles, California, United States, 90027

Kaiser Permenente

Oakland, California, United States, 94611

Children's Hospital of Orange County

Orange, California, United States, 92868

UCSF Medical Center at Mission Bay - Pediatric Oncology

San Francisco, California, United States, 94158

United States, Colorado

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

United States, Delaware

Nemours/ Alfred I. duPont Hospital for Children

Wilmington, Delaware, United States, 19803

United States, District of Columbia

Children's National Medical Center

Washington, District of Columbia, United States, 20010

United States, Florida

Golisano Children's Hospital of Southwest Florida

Fort Myers, Florida, United States, 33908

University of Florida

Gainesville, Florida, United States, 32610

Nicklaus Children's Hospital

Miami, Florida, United States, 33155

United States, Hawaii

Kapi'olani Medical Center

Honolulu, Hawaii, United States, 96826

United States, Illinois

St Jude Midwest Affiliate

Peoria, Illinois, United States, 61637

United States, Indiana

Riley Hospital for Children - Indiana University

Indianapolis, Indiana, United States, 46202

United States, Kentucky

University of Louisville and Norton Children's Hospital

Louisville, Kentucky, United States, 40202

United States, Maryland

Johns Hopkins

Baltimore, Maryland, United States, 21287

United States, Massachusetts

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

United States, Michigan

CS Mott Children's Hospital

Ann Arbor, Michigan, United States, 48109

United States, Minnesota

University of Minnesota/Masonic Cancer Center

Minneapolis, Minnesota, United States, 55455

United States, Mississippi

University of Mississippi Medical Center

Jackson, Mississippi, United States, 39216

United States, Missouri

Children's Mercy Hospital and Clinics

Kansas City, Missouri, United States, 64108

United States, Nevada

Alliance for Childhood Diseases

Las Vegas, Nevada, United States, 89135

United States, New Jersey

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Morristown Medical Center

Morristown, New Jersey, United States, 07960

Rutgers cancer Institute of NJ

New Brunswick, New Jersey, United States, 08901

United States, New York

Cohen Children's Medical Center

New Hyde Park, New York, United States, 11040

Columbia University/Herbert Irving Cancer Center

New York, New York, United States, 10032

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

New York Medical College

Valhalla, New York, United States, 10595

United States, Ohio

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Nationwide Children's Hospital

Columbus, Ohio, United States, 43205

United States, Oklahoma

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States, 73104

United States, Oregon

Oregon Health & Science University

Portland, Oregon, United States, 97239

United States, Pennsylvania

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States, 15224

United States, Tennessee

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

United States, Texas

Dell Children's Medical Center of Central Texas

Austin, Texas, United States, 78723

The University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Cook Children's Medical Center

Fort Worth, Texas, United States, 76104

Texas Children's Hospital

Houston, Texas, United States, 77030

The Children's Hospital of San Antonio

San Antonio, Texas, United States, 78207

United States, Virginia

Children's Hospital of The King's Daughters

Norfolk, Virginia, United States, 23507

United States, Washington

Seattle Children's Hospital

Seattle, Washington, United States, 98105

Canada, Nova Scotia

IWK Health Centre

Halifax, Nova Scotia, Canada, B3K 6R8

Canada, Ontario

Hospital for Sick Children

Toronto, Ontario, Canada, M5G 1X8

Canada, Quebec

Montreal Children's Hospital

Montreal, Quebec, Canada, H4A3J1

Sponsors and Collaborators

Eisai Inc.

Merck Sharp & Dohme LLC

More Information

• Responsible Party: Eisai Inc.
• ClinicalTrials.gov Identifier: NCT03245151
• Other Study ID Numbers: E7080-A001-216
• First Posted: August 10, 2017
• Last Update Posted: January 30, 2023
• Last Verified: November 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Eisai Inc.:

pediatrics; central nervous system tumors; lenvatinib; E7080; everolimus; Ewing sarcoma/peripheral primitive neuroectodermal tumor; rhabdomyosarcoma; high grade glioma; solid tumors

Additional relevant MeSH terms:

Central Nervous System Neoplasms; Recurrence; Neoplasms; Disease Attributes; Pathologic Processes; Nervous System Neoplasms; Neoplasms by Site; Nervous System Diseases; Everolimus; Lenvatinib; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action